UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
August 28, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
|
Form
20-F x
|
Form 40-F o |
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes
o
|
No x |
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 28,
2007
is hereby incorporated by reference into the registration statement on Form
F-3
(File No. 333-141529) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007.
Processing
Fees on ADRs to be Waived for Two Months
Valley
Cottage, New York, August 28, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical
company engaged in the acquisition, development and commercialization of
therapeutics for the treatment of unmet medical needs, particularly neuropathic
pain and hepatitis C, today announced that issuances of American Depositary
Receipts, or ADRs, by the Company’s depositary bank, The Bank of New York, will
be processed free of the customary charges of The Bank of New York from
September 3, 2007 through October 31, 2007.
The
Bank
of New York will issue ADRs representing American Depositary Shares, or ADSs,
if
shareholders or their broker deposit Ordinary Shares with The Bank of New York’s
Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London
office of The Bank of New York. One ADR will represent an ownership interest
in
ten of XTL's Ordinary Shares.
Interested
investors should contact their brokers to discuss the waived fee and should
they
have any questions, can contact The Bank of New York in either London or New
York as follows:
|
London
|
or
|
New
York
|
|
Mark
Lewis
|
Jason
Paltrowitz
|
|
|
Vice
President
|
Vice
President
|
|
|
Tel
020.7964.6089
|
Tel
212.815.2077
|
|
|
Fax
020.7964.6024
|
Fax
212.815.3004
|
|
|
marlewis@bankofny.com
|
jpaltrowitz@bankofny.com
|
|
Ron
Bentsur, Chief Executive Officer of XTL, commented, “We want to thank The Bank
of New York for offering shareholders this free issuance window in conjunction
with the planned cancellation of the Company’s Ordinary Shares on the Official
List of the United Kingdom Listing Authority, subject to shareholder approval
at
an Extraordinary General Meeting to be held on September 25, 2007.”
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and
commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded on
the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
| Tel: |
+1-(845)-267-0707
ext. 225
|
| +972-8-930-4444 |
Cautionary
Statement
Some
of the statements included in this press release, particularly those
anticipating continued undisrupted trading of the Company’s ADRs on NASDAQ or
the future cancellation of the Company’s Ordinary Shares on the Official List of
the United Kingdom Listing Authority and similar matters, may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.
Risk factors that could adversely affect our operations are identified from
time
to time in our reports filed with the Securities and Exchange Commission and
the
London Stock Exchange, including our annual report on Form 20-F filed with
the
Securities and Exchange Commission on March 23, 2007. Any forward-looking
statements set forth in this press release speak only as of the date of this
press release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at http://www.xtlbio.com.
The information in our website is not incorporated by reference into this press
release and is included as an inactive textual reference only. This press
release is for informational purposes only and is not an offer to by or the
solicitation of an offer to sell any securities.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: August 28, 2007 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
| Chief Executive Officer | ||